{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018868","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.313926+00:00","generated_at":"2026-06-25T22:17:30.709025+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma Q1 2022 cash $98.7M; on track for registrational study in pulmonary sarcoidosis","bullets":["Cash and investments $98.7M at March 31, 2022; R&D expenses $8.9M, G&A $3.5M.","Phase 1b/2a efzofitimod data to be presented at ATS 2022; registrational study planned for Q3 2022.","FDA orphan drug designation for efzofitimod in systemic sclerosis; exploring expansion into other ILDs.","ATYR2810 IND candidate; Phase 1 study in cancer expected in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018868","json":"https://secwatch.observer/filing/0001564590-22-018868.json","markdown":"https://secwatch.observer/filing/0001564590-22-018868.md","text":"https://secwatch.observer/filing/0001564590-22-018868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022018868/0001564590-22-018868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022018868/life-8k_20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:17:30.709025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}